Protocol Ledger

NCT07284134 · Phase III · RECRUITING

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Interventional Phase III clinical trial protocol NCT07284134 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-24 Enrollment: 560 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07284134
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)560 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07284134
Protocol FieldVerified Registry Value
NCT IdentifierNCT07284134
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment560 participants (ESTIMATED)
Registered Start Date2025-12-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI